Project Grant K99HL177417
Award Date
7/20/25
Completion Date
5/31/27
Dollars Obligated
$113K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), supports research under the Cardiovascular Diseases Research program (CFDA 93.837). The $117,804 award to The Leland Stanford Junior University (Stanford University) aims to investigate the role of macrophages and T-cell recruitment in immune checkpoint inhibitor-induced myocarditis, a life-threatening side effect of cancer immunotherapies. Specifically,...
This Project Grant award of $858,186 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) supports research by The General Hospital Corporation (doing business as Massachusetts General Hospital) to decipher the mechanisms leading to immune-related myocarditis, a fatal adverse event associated with immune checkpoint inhibitor (ICI) cancer therapies. The research aims to identify novel...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $694,754 to The Washington University in St. Louis to conduct research on understanding the molecular and cellular mechanisms underlying cardiomyopathies and identifying potential therapeutic interventions. The key objectives are to: 1) determine if patient mutations in the troponin gene can be grouped based on common molecular...
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to characterize the anti-inflammatory role of the CX3CR1+ conventional dendritic cell type 2 (CX3CR1+CDC2) subset in allergic lung inflammation. The $760,759 award to the University of Illinois aims to determine the mechanisms by which this CDC2 subset regulates allergic lung inflammation, including its ability to drive...
The National Cancer Institute (NCI) awarded a $547,945 Project Grant under CFDA 93.396 (Cancer Biology Research) to The Johns Hopkins University to conduct research on the pathogenesis of immune checkpoint inhibitor-induced myocarditis. The project aims to investigate how biological factors such as prior cardiac injury, age, and sex modulate the risk of this adverse event, which occurs in 1-2% of cancer patients receiving immune checkpoint inhibitor therapy but can be fatal in up to 50% of...
This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research supports research to investigate the interactions between human T cells and cardiomyocytes (heart muscle cells) in immune checkpoint inhibitor-related myocarditis. The $197,640 award to The General Hospital Corporation (doing business as Massachusetts General Hospital) aims to decipher the drivers of this severe and potentially...
This $144,362 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to investigate the immunologic mechanisms underlying the development of Chagas cardiomyopathy, a debilitating heart condition that affects 30-40% of individuals infected with Trypanosoma cruzi. The research will use advanced techniques like single-cell RNA sequencing and spatial transcriptomics to characterize the immune cell...
The federal Project Grant award of $673,642 from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research aims to investigate the role of lysosomes in contributing to arrhythmic risk and sudden cardiac death in ischemic heart failure. The primary objectives are to: 1) Determine whether a lysosomal-sarcoplasmic reticulum (SR) microdomain exists in ischemic heart failure; 2) Evaluate whether TRPML1-mediated lysosomal Ca2+ release can trigger SR...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) at the National Institutes of Health provides $167,864 to The Leland Stanford Junior University to investigate risk stratification and outcomes across the spectrum of cardiotoxicity from immune checkpoint inhibitor cancer therapies. The study aims to: 1) retrospectively examine cardiac and oncologic outcomes associated with immune checkpoint inhibitor cardiotoxicity based on...
This Project Grant award of $248,999 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research by Washington University to elucidate the mechanisms of cardiovascular toxicity associated with tyrosine kinase inhibitor (TKI) cancer treatments. The research aims to leverage patient-derived induced pluripotent stem cells to model TKI-induced vascular dysfunction and identify candidate compounds that can mitigate these adverse cardiovascular...